Generation Bio to Present at the 2024 TD Cowen Genetic Medicines & RNA Summit
CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff
JMP Securities Maintains Generation Bio(GBIO.US) With Hold Rating
JMP Securities analyst Silvan Tuerkcan maintains $Generation Bio(GBIO.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 36.4% and a total average return of 4.1% ove
Analysts' Opinions Are Mixed on These Healthcare Stocks: Generation Bio (GBIO), LAVA Therapeutics (LVTX) and Aura Biosciences Inc (AURA)
Generation Bio Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Sales Results.
Generation Bio Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Sales Results.
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersDelcath Systems (NASDAQ:DCTH) stock rose 33.2% to $7.19 during Tuesday's regular session. The company's market cap stands at $199.8 million. As per the news, the Q1 earnings report came out tod
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO) and Generation Bio (GBIO)
Express News | Wedbush Reiterates Outperform on Generation Bio, Maintains $5 Price Target
Wedbush Remains a Buy on Generation Bio (GBIO)
Analysts Offer Insights on Healthcare Companies: Wuxi Biologics (Cayman) (OtherWXIBF) and Generation Bio (GBIO)
Express News | Generation Bio Q1 2024 Adj EPS $(1.12) Misses $(0.41) Estimate, Sales $4.059M Beat $1.920M Estimate
Generation Bio | 10-Q: Quarterly report
Express News | Generation Bio Co: Cash Balance of $233.9 Mln Still Expected to Fund Operations Into 2H 2027
Express News | Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results
Press Release: Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results
Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results
Generation Bio 1Q Loss/Shr $1.12 >GBIO
Generation Bio 1Q Loss/Shr $1.12 >GBIO
Express News | Generation Bio Q1 Basic EPS USD -1.12
Express News | Generation Bio Q1 Operating Expenses USD 81.693 Million
Express News | Generation Bio Q1 Operating Income USD -77.634 Million
Generation Bio Announces the Presentation of Preclinical Data on IqDNA and CtLNP Platforms at the ASGCT 27th Annual Meeting
Data presented show immune-quiet DNA (iqDNA) is a partially single-stranded DNA cargo that maintains expression while evading innate immune sensorsRapid enzymatic synthesis continues to improve iqDNA
Express News | Bioceres Crop Solutions Corp - Announces Brazil's Approval of New Generation Bio-Insecticide
No Data